ArticleMethods (San Diego, Calif.)2018
Design, Assembly, Production, and Transfection of Synthetic Modified mRNA.
Article in Methods (San Diego, Calif.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Article
- mRNA-Lipid Nanoparticle-Mediated Reprogramming and Standard Sendai Virus Reprogramming: Generation of iPSCs and iPSC-Derived Cardiomyocytes.International journal of molecular sciences · 2026Article
- The design, manufacture and LNP formulation of mRNA for research use.Nature protocols · 2025Article
- Position-specific ORF nucleoside-ribose modifications enabled by complete chemical synthesis enhance mRNA stability and translation.Nature communications · 2025Article
- Investigating RNA dynamics from single molecule transcriptomes.Trends in genetics : TIG · 2025Review
- Review
- Review
- Research progress of mosquito-borne virus mRNA vaccines.Molecular therapy. Methods & clinical development · 2025Review
- Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Barriers in Heart Failure Gene Therapy and Approaches to Overcome Them.Heart, lung & circulation · 2023Article
- Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.Tissue engineering and regenerative medicine · 2023Review
- Field Evaluation of a Safe, Easy, and Low-Cost Protocol for Shipment of Samples from Suspected Cases of Foot-and-Mouth Disease to Diagnostic Laboratories.Transboundary and emerging diseases · 2023Article
- Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell andMolecular therapy. Nucleic acids · 2022Article
- Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions.Antibodies (Basel, Switzerland) · 2022Review
- Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2.Science advances · 2022Article
- Review
- mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles.Biomedicines · 2021Review
- Could live attenuated vaccines better control COVID-19?Vaccine · 2021Review
- mRNA vaccine for cancer immunotherapy.Molecular cancer · 2021Review
- mRNA vaccines for COVID-19: what, why and how.International journal of biological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Proteins are drivers of cell functions and are targets of many therapies. Exogenous protein expression techniques, therefore, have been essential for research and medicine. The most common method for exogenous protein expression relies on DNA-based viral or non-viral vectors. However, DNA-based vectors have the potential to integrate into the host genome and cause permanent mutations. RNA-based vectors solve this shortcoming. In particular, synthetic modified mRNA provides non-viral, integration-free, zero-footprint method for expressing proteins. Modified mRNA can direct cell fate specification and cellular reprogramming faster and more efficiently than other methods. Furthermore, when simultaneously express multiple different proteins, mRNA vectors allow for greater flexibility and control over stoichiometric ratios, dose titrations, and complete silencing of expressions. Additionally, modified mRNAs have been shown to be viable and safe as therapeutic agents for gene therapy and vaccine, providing an alternative approach to address diseases. Despite these advantages, technical challenge, mRNA instability, and host immunogenicity have caused significant barriers to widespread use of this technology. The comprehensive method presented here addresses all of these shortcomings. This stepwise protocol describes every step necessary for the synthesis of modified mRNA from any coding DNA sequence of interest. The meticulously detailed protocol enables the users to make alterations to each component of modified mRNA for even more significant customization, allowing the researchers to apply this technology to a wide range of uses. This non-cytotoxic synthetic modified mRNA can be used for protein expression, regulation of cell reprogramming or differentiation, and drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.